StreetInsider.com News Articles

Insulet launches Omnipod Discover data platform in the U.S.

Mon, 12 Oct 2026 07:01:12 -0400

Insulet Corporation (NASDAQ: PODD) has announced the full U.S. market release of Omnipod Discover, a web-based data platform designed for users of its Omnipod 5 automated insulin delivery system, their caregivers, and healthcare professionals.

The platform converts diabetes data into visualizations and personalized insights, and delivers weekly glucose and insulin delivery reports to users' smartphones. For healthcare professionals, the platform overlays a licensed Ambulatory Glucose Profile with adjustable pump settings and bolus events to support clinical decision-making.

According to the company, more than 15,000 Omnipod 5 users and over 1,800 healthcare professionals had already adopted the platform during a limited U.S. market

Insulet Announces Omnipod Discover Now Available in U.S.

Mon, 12 Oct 2026 07:00:00 -0400

Web-based data platform turns Omnipod 5 data into clear, personalized insights for users, caregivers, and healthcare professionals

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. full market release of Omnipod Discover™, a web-based data platform designed for Omnipod 5 users, their caregivers, and healthcare providers (HCPs). Omnipod Discover turns critical diabetes data into clear visualizations and personalized insights, giving people with diabetes and their HCPs a shared understanding of therapy patterns to make more informed diabetes

Insulet Announces Omnipod Discover Now Available in U.S.

Mon, 12 Oct 2026 07:00:00 -0400

Web-based data platform turns Omnipod 5 data into clear, personalized insights for users, caregivers, and healthcare professionals

Insulet Corporation (PODD) PT Lowered to $190 at Jefferies

Mon, 12 Oct 2026 05:21:21 -0400

Jefferies analyst Matthew Taylor lowered the price target on Insulet Corporation (NASDAQ: PODD) to $190.00 (from $275.00) while maintaining a Buy rating.

The analyst comments "Alongside our diabetes survey (link), we are launching coverage on BBNX (Toomey, Buy) and MMED (Toomey, Hold) and lowering our PODD #s and PT to account for share loss given multiple competitive launches over the NTM. Despite this, we are keeping our Buy rating, as we think much of this has been priced in, and note PODD's offering continues to be viewed positively by docs and is well positioned in T2, where our survey points to

Insulet Corporation (PODD) PT Lowered to $190 at Jefferies

Mon, 12 Oct 2026 05:21:21 -0400

Jefferies analyst Matthew Taylor lowered the price target on Insulet Corporation (NASDAQ: PODD) to $190.00 (from $275.00) while maintaining a Buy rating.

Barclays Starts Insulet Corporation (PODD) at Equalweight

Tue, 06 Oct 2026 16:26:10 -0400

Barclays analyst Matt Miksic initiates coverage on Insulet Corporation (NASDAQ: PODD) with a Equalweight rating and a price target of $150.00.

For an analyst ratings summary and ratings history on Insulet Corporation click here. For more ratings news on Insulet Corporation click here.

Shares of Insulet Corporation closed at $135.62 yesterday.

Form 4 INSULET CORP For: Oct 01 Filed by: Pease Flavia

Mon, 05 Oct 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20261005/27150178.html

Form 4 INSULET CORP For: Sep 30 Filed by: MAZELSKY JONATHAN JAY

Fri, 02 Oct 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20261002/27142635.html

Form 4 INSULET CORP For: Sep 30 Filed by: Huffines Robert Luther

Fri, 02 Oct 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20261002/27142574.html

Important Notice to Long-Term Shareholders of Beta Bionics, Inc. (NASDAQ: BBNX); Better Home & Finance Holding Company (NASDAQ: BETR); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: POD

Thu, 01 Oct 2026 08:26:59 -0400

PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) --

Beta Bionics, Inc. (NASDAQ: BBNX):

Grabar Law Office is investigating claims on behalf of shareholders of Beta Bionics, Inc. (NASDAQ: BBNX).

What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Beta Bionics, Inc. (NASDAQ: BBNX) shares prior to July 30, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at

Important Notice to Long-Term Shareholders of Beta Bionics, Inc. (NASDAQ: BBNX); Better Home & Finance Holding Company (NASDAQ: BETR); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: POD

Thu, 01 Oct 2026 08:26:59 -0400

PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) --

Beta Bionics, Inc. (NASDAQ: BBNX):

Grabar Law Office is investigating claims on behalf of shareholders of Beta Bionics, Inc. (NASDAQ: BBNX).

What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Beta Bionics, Inc. (NASDAQ: BBNX) shares prior to July 30, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at

Important Notice to Long-Term Shareholders of Beta Bionics, Inc. (NASDAQ: BBNX); Better Home & Finance Holding Company (NASDAQ: BETR); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: POD

Thu, 01 Oct 2026 08:26:59 -0400

PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) --

Beta Bionics, Inc. (NASDAQ: BBNX):

Grabar Law Office is investigating claims on behalf of shareholders of Beta Bionics, Inc. (NASDAQ: BBNX).

What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Beta Bionics, Inc. (NASDAQ: BBNX) shares prior to July 30, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at

Important Notice to Long-Term Shareholders of Beta Bionics, Inc. (NASDAQ: BBNX); Better Home & Finance Holding Company (NASDAQ: BETR); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: POD

Thu, 01 Oct 2026 08:26:59 -0400

PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) --

Beta Bionics, Inc. (NASDAQ: BBNX):

Grabar Law Office is investigating claims on behalf of shareholders of Beta Bionics, Inc. (NASDAQ: BBNX).

What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Beta Bionics, Inc. (NASDAQ: BBNX) shares prior to July 30, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at

Important Notice to Long-Term Shareholders of Beta Bionics, Inc. (NASDAQ: BBNX); Better Home & Finance Holding Company (NASDAQ: BETR); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: POD

Thu, 01 Oct 2026 08:26:59 -0400

PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) --

Beta Bionics, Inc. (NASDAQ: BBNX):

Grabar Law Office is investigating claims on behalf of shareholders of Beta Bionics, Inc. (NASDAQ: BBNX).

What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Beta Bionics, Inc. (NASDAQ: BBNX) shares prior to July 30, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at

Important Notice to Long-Term Shareholders of Beta Bionics, Inc. (NASDAQ: BBNX); Better Home & Finance Holding Company (NASDAQ: BETR); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: POD

Thu, 01 Oct 2026 08:26:59 -0400

PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) --

Beta Bionics, Inc. (NASDAQ: BBNX):

Grabar Law Office is investigating claims on behalf of shareholders of Beta Bionics, Inc. (NASDAQ: BBNX).

What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Beta Bionics, Inc. (NASDAQ: BBNX) shares prior to July 30, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at

Important Notice to Long-Term Shareholders of Beta Bionics, Inc. (NASDAQ: BBNX); Better Home & Finance Holding Company (NASDAQ: BETR); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: POD

Thu, 01 Oct 2026 08:26:59 -0400

PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) --

Beta Bionics, Inc. (NASDAQ: BBNX):

Grabar Law Office is investigating claims on behalf of shareholders of Beta Bionics, Inc. (NASDAQ: BBNX).

What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Beta Bionics, Inc. (NASDAQ: BBNX) shares prior to July 30, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at

Important Notice to Long-Term Shareholders of Beta Bionics, Inc. (NASDAQ: BBNX); Better Home & Finance Holding Company (NASDAQ: BETR); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: POD

Thu, 01 Oct 2026 08:26:59 -0400

PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) --

Beta Bionics, Inc. (NASDAQ: BBNX):

Grabar Law Office is investigating claims on behalf of shareholders of Beta Bionics, Inc. (NASDAQ: BBNX).

What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Beta Bionics, Inc. (NASDAQ: BBNX) shares prior to July 30, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at

Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026

Thu, 01 Oct 2026 07:00:00 -0400

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time).
The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, “Events and

Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026

Thu, 01 Oct 2026 07:00:00 -0400

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time).
The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, “Events and

CMS pumps $51M into rural Texas to fight diabetes and obesity

Mon, 28 Sep 2026 10:10:24 -0400

Investing.com - The federal government is deploying $51 million to 68 rural Texas hospital districts to build and expand chronic disease prevention programs targeting diabetes, cardiovascular disease, respiratory illness, and obesity, according to a CMS announcement dated September 28, 2026. The funding is the first visible tranche of Texas's $281 million first-year allocation from the $50 billion Rural Health Transformation Program (RHTP), itself established by the Working Families Tax Cuts Act.
At roughly $750,000 per district, the individual tranche is modest on its own — but institutional investors should read it as a structural demand signal: Texas alone is slated for

CMS pumps $51M into rural Texas to fight diabetes and obesity

Mon, 28 Sep 2026 10:10:24 -0400

Investing.com - The federal government is deploying $51 million to 68 rural Texas hospital districts to build and expand chronic disease prevention programs targeting diabetes, cardiovascular disease, respiratory illness, and obesity, according to a CMS announcement dated September 28, 2026. The funding is the first visible tranche of Texas's $281 million first-year allocation from the $50 billion Rural Health Transformation Program (RHTP), itself established by the Working Families Tax Cuts Act.
At roughly $750,000 per district, the individual tranche is modest on its own — but institutional investors should read it as a structural demand signal: Texas alone is slated for

CMS pumps $51M into rural Texas to fight diabetes and obesity

Mon, 28 Sep 2026 10:10:24 -0400

Investing.com - The federal government is deploying $51 million to 68 rural Texas hospital districts to build and expand chronic disease prevention programs targeting diabetes, cardiovascular disease, respiratory illness, and obesity, according to a CMS announcement dated September 28, 2026. The funding is the first visible tranche of Texas's $281 million first-year allocation from the $50 billion Rural Health Transformation Program (RHTP), itself established by the Working Families Tax Cuts Act.
At roughly $750,000 per district, the individual tranche is modest on its own — but institutional investors should read it as a structural demand signal: Texas alone is slated for

CMS pumps $51M into rural Texas to fight diabetes and obesity

Mon, 28 Sep 2026 10:10:24 -0400

Investing.com - The federal government is deploying $51 million to 68 rural Texas hospital districts to build and expand chronic disease prevention programs targeting diabetes, cardiovascular disease, respiratory illness, and obesity, according to a CMS announcement dated September 28, 2026. The funding is the first visible tranche of Texas's $281 million first-year allocation from the $50 billion Rural Health Transformation Program (RHTP), itself established by the Working Families Tax Cuts Act.
At roughly $750,000 per district, the individual tranche is modest on its own — but institutional investors should read it as a structural demand signal: Texas alone is slated for

CMS pumps $51M into rural Texas to fight diabetes and obesity

Mon, 28 Sep 2026 10:10:24 -0400

Investing.com - The federal government is deploying $51 million to 68 rural Texas hospital districts to build and expand chronic disease prevention programs targeting diabetes, cardiovascular disease, respiratory illness, and obesity, according to a CMS announcement dated September 28, 2026. The funding is the first visible tranche of Texas's $281 million first-year allocation from the $50 billion Rural Health Transformation Program (RHTP), itself established by the Working Families Tax Cuts Act.
At roughly $750,000 per district, the individual tranche is modest on its own — but institutional investors should read it as a structural demand signal: Texas alone is slated for

CMS pumps $51M into rural Texas to fight diabetes and obesity

Mon, 28 Sep 2026 10:10:24 -0400

Investing.com - The federal government is deploying $51 million to 68 rural Texas hospital districts to build and expand chronic disease prevention programs targeting diabetes, cardiovascular disease, respiratory illness, and obesity, according to a CMS announcement dated September 28, 2026. The funding is the first visible tranche of Texas's $281 million first-year allocation from the $50 billion Rural Health Transformation Program (RHTP), itself established by the Working Families Tax Cuts Act.
At roughly $750,000 per district, the individual tranche is modest on its own — but institutional investors should read it as a structural demand signal: Texas alone is slated for